US Patent
US12133837 — Epinephrine compositions and containers
Formulation · Assigned to Nevakar Injectables Inc · Expires 2039-03-21 · 13y remaining
Vulnerability score
55/100
Moderate — design-around opportunities exist
What this patent protects
This patent protects epinephrine compositions with improved stability that can be packaged using blow-fill-seal technology or flexible IV bags.
USPTO Abstract
The inventive subject matter provides ready-to-administer, preferably anti-oxidant free, epinephrine compositions with improved stability, and methods for preparing the same. Contemplated compositions can be packaged using blow-fill-seal technology or packaged into flexible IV bags and maintain degradation of the epinephrine at a level of less than 5 wt % when stored over at least one months at between 2-40° C.
Drugs covered by this patent
- Epipen (epinephrine) · Pfizer Inc.
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.